Effect of angiotensin-converting enzyme inhibition on cardiovascular adaptation to exercise training. 2022

Tórur Sjúrðarson, and Jacob Bejder, and Andreas Breenfeldt Andersen, and Thomas Bonne, and Kasper Kyhl, and Tóra Róin, and Poula Patursson, and Noomi Oddmarsdóttir Gregersen, and May-Britt Skoradal, and Michael Schliemann, and Malte Lindegaard, and Pál Weihe, and Magni Mohr, and Nikolai B Nordsborg
Center of Health Science, Faculty of Health Science, University of the Faroe Islands, Tórshavn, Faroe Islands.

Angiotensin-converting enzyme (ACE) activity may be one determinant of adaptability to exercise training, but well-controlled studies in humans without confounding conditions are lacking. Thus, the purpose of the present study was to investigate whether ACE inhibition affects cardiovascular adaptations to exercise training in healthy humans. Healthy participants of both genders (40 ± 7 years) completed a randomized, double-blind, placebo-controlled trial. Eight weeks of exercise training combined with placebo (PLA, n = 25) or ACE inhibitor (ACEi, n = 23) treatment was carried out. Before and after the intervention, cardiovascular characteristics were investigated. Mean arterial blood pressure was reduced (p < 0.001) by -5.5 [-8.4; -2.6] mmHg in ACEi , whereas the 0.7 [-2.0; 3.5] mmHg fluctuation in PLA was non-significant. Maximal oxygen uptake increased (p < 0.001) irrespective of ACE inhibitor treatment by 13 [8; 17] % in ACEi and 13 [9; 17] % in PLA. In addition, skeletal muscle endurance increased (p < 0.001) to a similar extent in both groups, with magnitudes of 82 [55; 113] % in ACEi and 74 [48; 105] % in PLA. In contrast, left atrial volume decreased (p < 0.05) by -9 [-16; -2] % in ACEi , but increased (p < 0.01) by 14 [5; 23] % in PLA. Total hemoglobin mass was reduced (p < 0.01) by -3 [-6; -1] % in ACEi , while a non-significant numeric increase of 2 [-0.4; 4] % existed in PLA. The lean mass remained constant in ACEi but increased (p < 0.001) by 3 [2; 4] % in PLA. In healthy middle-aged adults, 8 weeks of high-intensity exercise training increases maximal oxygen uptake and skeletal muscle endurance irrespective of ACE inhibitor treatment. However, ACE inhibitor treatment counteracts exercise training-induced increases in lean mass and left atrial volume. ACE inhibitor treatment compromises total hemoglobin mass.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010100 Oxygen An element with atomic symbol O, atomic number 8, and atomic weight [15.99903; 15.99977]. It is the most abundant element on earth and essential for respiration. Dioxygen,Oxygen-16,Oxygen 16
D002319 Cardiovascular System The HEART and the BLOOD VESSELS by which BLOOD is pumped and circulated through the body. Circulatory System,Cardiovascular Systems,Circulatory Systems
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D005260 Female Females
D006454 Hemoglobins The oxygen-carrying proteins of ERYTHROCYTES. They are found in all vertebrates and some invertebrates. The number of globin subunits in the hemoglobin quaternary structure differs between species. Structures range from monomeric to a variety of multimeric arrangements. Eryhem,Ferrous Hemoglobin,Hemoglobin,Hemoglobin, Ferrous
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000806 Angiotensin-Converting Enzyme Inhibitors A class of drugs whose main indications are the treatment of hypertension and heart failure. They exert their hemodynamic effect mainly by inhibiting the renin-angiotensin system. They also modulate sympathetic nervous system activity and increase prostaglandin synthesis. They cause mainly vasodilation and mild natriuresis without affecting heart rate and contractility. ACE Inhibitor,ACE Inhibitors,Angiotensin Converting Enzyme Inhibitor,Angiotensin I-Converting Enzyme Inhibitor,Angiotensin-Converting Enzyme Inhibitor,Kininase II Inhibitor,Kininase II Inhibitors,Angiotensin I-Converting Enzyme Inhibitors,Angiotensin-Converting Enzyme Antagonists,Antagonists, Angiotensin-Converting Enzyme,Antagonists, Kininase II,Inhibitors, ACE,Inhibitors, Angiotensin-Converting Enzyme,Inhibitors, Kininase II,Kininase II Antagonists,Angiotensin Converting Enzyme Antagonists,Angiotensin Converting Enzyme Inhibitors,Angiotensin I Converting Enzyme Inhibitor,Angiotensin I Converting Enzyme Inhibitors,Antagonists, Angiotensin Converting Enzyme,Enzyme Antagonists, Angiotensin-Converting,Enzyme Inhibitor, Angiotensin-Converting,Enzyme Inhibitors, Angiotensin-Converting,II Inhibitor, Kininase,Inhibitor, ACE,Inhibitor, Angiotensin-Converting Enzyme,Inhibitor, Kininase II,Inhibitors, Angiotensin Converting Enzyme

Related Publications

Tórur Sjúrðarson, and Jacob Bejder, and Andreas Breenfeldt Andersen, and Thomas Bonne, and Kasper Kyhl, and Tóra Róin, and Poula Patursson, and Noomi Oddmarsdóttir Gregersen, and May-Britt Skoradal, and Michael Schliemann, and Malte Lindegaard, and Pál Weihe, and Magni Mohr, and Nikolai B Nordsborg
November 2004, Journal of cardiovascular pharmacology,
Tórur Sjúrðarson, and Jacob Bejder, and Andreas Breenfeldt Andersen, and Thomas Bonne, and Kasper Kyhl, and Tóra Róin, and Poula Patursson, and Noomi Oddmarsdóttir Gregersen, and May-Britt Skoradal, and Michael Schliemann, and Malte Lindegaard, and Pál Weihe, and Magni Mohr, and Nikolai B Nordsborg
January 2006, Preventive cardiology,
Tórur Sjúrðarson, and Jacob Bejder, and Andreas Breenfeldt Andersen, and Thomas Bonne, and Kasper Kyhl, and Tóra Róin, and Poula Patursson, and Noomi Oddmarsdóttir Gregersen, and May-Britt Skoradal, and Michael Schliemann, and Malte Lindegaard, and Pál Weihe, and Magni Mohr, and Nikolai B Nordsborg
May 2005, Circulation,
Tórur Sjúrðarson, and Jacob Bejder, and Andreas Breenfeldt Andersen, and Thomas Bonne, and Kasper Kyhl, and Tóra Róin, and Poula Patursson, and Noomi Oddmarsdóttir Gregersen, and May-Britt Skoradal, and Michael Schliemann, and Malte Lindegaard, and Pál Weihe, and Magni Mohr, and Nikolai B Nordsborg
January 1990, Circulation,
Tórur Sjúrðarson, and Jacob Bejder, and Andreas Breenfeldt Andersen, and Thomas Bonne, and Kasper Kyhl, and Tóra Róin, and Poula Patursson, and Noomi Oddmarsdóttir Gregersen, and May-Britt Skoradal, and Michael Schliemann, and Malte Lindegaard, and Pál Weihe, and Magni Mohr, and Nikolai B Nordsborg
March 1988, The American journal of medicine,
Tórur Sjúrðarson, and Jacob Bejder, and Andreas Breenfeldt Andersen, and Thomas Bonne, and Kasper Kyhl, and Tóra Róin, and Poula Patursson, and Noomi Oddmarsdóttir Gregersen, and May-Britt Skoradal, and Michael Schliemann, and Malte Lindegaard, and Pál Weihe, and Magni Mohr, and Nikolai B Nordsborg
June 1974, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.),
Tórur Sjúrðarson, and Jacob Bejder, and Andreas Breenfeldt Andersen, and Thomas Bonne, and Kasper Kyhl, and Tóra Róin, and Poula Patursson, and Noomi Oddmarsdóttir Gregersen, and May-Britt Skoradal, and Michael Schliemann, and Malte Lindegaard, and Pál Weihe, and Magni Mohr, and Nikolai B Nordsborg
April 1996, Journal of clinical pharmacology,
Tórur Sjúrðarson, and Jacob Bejder, and Andreas Breenfeldt Andersen, and Thomas Bonne, and Kasper Kyhl, and Tóra Róin, and Poula Patursson, and Noomi Oddmarsdóttir Gregersen, and May-Britt Skoradal, and Michael Schliemann, and Malte Lindegaard, and Pál Weihe, and Magni Mohr, and Nikolai B Nordsborg
January 1977, The Journal of international medical research,
Tórur Sjúrðarson, and Jacob Bejder, and Andreas Breenfeldt Andersen, and Thomas Bonne, and Kasper Kyhl, and Tóra Róin, and Poula Patursson, and Noomi Oddmarsdóttir Gregersen, and May-Britt Skoradal, and Michael Schliemann, and Malte Lindegaard, and Pál Weihe, and Magni Mohr, and Nikolai B Nordsborg
March 1991, American journal of hypertension,
Tórur Sjúrðarson, and Jacob Bejder, and Andreas Breenfeldt Andersen, and Thomas Bonne, and Kasper Kyhl, and Tóra Róin, and Poula Patursson, and Noomi Oddmarsdóttir Gregersen, and May-Britt Skoradal, and Michael Schliemann, and Malte Lindegaard, and Pál Weihe, and Magni Mohr, and Nikolai B Nordsborg
November 2016, The Journal of pharmacy and pharmacology,
Copied contents to your clipboard!